Breathtec Provides Update on FAIMS Breathalyzer Development Program (Globe Newswire)

UF startup Breathtec Biomedical Inc. is pleased to report on the development of its Breathtec Disease Detection Breathalyzer prototype (V3) based on the FAIMS (field asymmetric waveform ion mobility spectrometry) technology. The company announced that it has amended its research agreement with the University of Florida’s Analytical Chemistry Department, where Dr. Richard Yost, the principal investigator, will work to advance the V3 prototype, or future iterations, through its final stages of prototype development. Dr. Yost is one of the world’s foremost experts on FAIMS technology and has been a scientific advisor with the company since 2016.

Before the V3 prototype development phase is successfully completed, the device will need to achieve a number of performance characteristics including device sensitivity, precision and reproducibility in a laboratory setting. Once the prototype work is completed, the device will be ready to be moved into a research use only (RUO) development phase. The goal of this phase will be to engineer and produce field ready devices that will be made available to research scientists worldwide to help advance the discovery and validation of breath-based biomarkers.

Learn more about Breathtec Provides Update on FAIMS Breathalyzer Development Program.